Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine addresses the improvements that are needed in the future of closed-loop systems for diabetes treatment.
Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine addresses the improvements that are needed in the future of closed-loop systems for diabetes treatment.
Transcript (slightly modified)
What are the opportunities for improvement with the current closed-loop systems and how can they be addressed?
I know the system is approved but this is not the end of the closed-loop system research, it’s just the beginning actually, we are just starting.
We have a hybrid closed-loop system. It still requires users input for meals, you still have to count carbs, and in the background its adjusting insulin delivery. For future systems, our ultimate goal is the full automated system. It's on autopilot; you don’t have to worry about it, and it will deliver insulin, make adjustments, and in a way you can forget about diabetes—that’s the goal. To get there, we need better devices, maybe even smaller devices, better connection—so phone or other devices—and personalized medicine, like fine-tuning that insulin dose adjustments just for you.
I think we can do a lot more in that field and investigate closed-loop systems in populations like younger children and elderly so we can customize treatments for them. When you have a fast system, when you have a system that’s optimizing insulin delivery every 5 minutes, you need better insulins to keep up with that. It’s like you can’t think of using those old phone and internet connections with your iPads now. It might work, but you’re not going to get the best results with those old, slow internet connections. Like that, we need faster methods to accelerate insulin action so it can keep up with the system.
I think there is so much more, we are going to learn a lot, and this is going to also be a learning experience. Once we have more experience, we’ll have more questions and more ways to improve the system. But, the ultimate goal is just to have a system that is small, easy to use, and takes away all of the burden and fear of hypoglycemia so you can enjoy your life and the algorithm and device will do the work for you. So, that’s hopefully going to be the system of the near future.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More